ECSP19058322A - Extractos de plantas enriquecidos con derivados de ipolamiida como inmunosupresores para el tratamiento de trastornos inmunológicos - Google Patents

Extractos de plantas enriquecidos con derivados de ipolamiida como inmunosupresores para el tratamiento de trastornos inmunológicos

Info

Publication number
ECSP19058322A
ECSP19058322A ECSENADI201958322A ECDI201958322A ECSP19058322A EC SP19058322 A ECSP19058322 A EC SP19058322A EC SENADI201958322 A ECSENADI201958322 A EC SENADI201958322A EC DI201958322 A ECDI201958322 A EC DI201958322A EC SP19058322 A ECSP19058322 A EC SP19058322A
Authority
EC
Ecuador
Prior art keywords
treatment
plant extracts
immunosuppressors
immune disorders
extracts enriched
Prior art date
Application number
ECSENADI201958322A
Other languages
English (en)
Inventor
Carlos Eduardo Vitor
Fernando Henrique De Souza Gama
Alessandra Mascarello
Romulo Dragani Reis
Lisandra Ravanelli Pessa
Cristiano Ruch Werneck Guimarães
Original Assignee
Ache Laboratorios Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos Sa filed Critical Ache Laboratorios Farmaceuticos Sa
Publication of ECSP19058322A publication Critical patent/ECSP19058322A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/92—Unsaturated compounds containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención describe extractos de plantas del género Stachytarpheta enriquecidos con derivados de ipolamiida como inmunosupresores para el tratamiento de trastornos inmunológicos. También se describen compuestos activos aislados y un proceso de producción de los mismos.
ECSENADI201958322A 2017-02-17 2019-08-14 Extractos de plantas enriquecidos con derivados de ipolamiida como inmunosupresores para el tratamiento de trastornos inmunológicos ECSP19058322A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102017003318-0A BR102017003318A2 (pt) 2017-02-17 2017-02-17 compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas
PCT/BR2018/050037 WO2018148816A2 (en) 2017-02-17 2018-02-19 Compounds, process of production of compounds, enriched extract, enriched extract active fractions, enriched extract process of production, method for selecting vegetal biomass for enriched extract production, composition and use for treatment of immunological disorders

Publications (1)

Publication Number Publication Date
ECSP19058322A true ECSP19058322A (es) 2019-10-31

Family

ID=61282932

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201958322A ECSP19058322A (es) 2017-02-17 2019-08-14 Extractos de plantas enriquecidos con derivados de ipolamiida como inmunosupresores para el tratamiento de trastornos inmunológicos

Country Status (28)

Country Link
US (1) US12698265B2 (es)
EP (2) EP3583103B1 (es)
JP (2) JP7349362B2 (es)
KR (2) KR102882868B1 (es)
CN (1) CN110475768B (es)
AU (2) AU2018221956B2 (es)
BR (1) BR102017003318A2 (es)
CA (2) CA3052713A1 (es)
CL (1) CL2019002309A1 (es)
CO (1) CO2019008891A2 (es)
CY (1) CY1125187T1 (es)
DK (1) DK3583103T3 (es)
EC (1) ECSP19058322A (es)
ES (1) ES2909387T3 (es)
HR (1) HRP20220377T1 (es)
IL (2) IL268732B2 (es)
LT (1) LT3583103T (es)
MX (2) MX2019009655A (es)
PE (2) PE20242300A1 (es)
PL (1) PL3583103T3 (es)
PT (1) PT3583103T (es)
RS (1) RS63162B1 (es)
SA (1) SA519402443B1 (es)
SG (1) SG11201907375VA (es)
SI (1) SI3583103T1 (es)
SM (1) SMT202200121T1 (es)
WO (1) WO2018148816A2 (es)
ZA (2) ZA201906106B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102017003318A2 (pt) 2017-02-17 2018-10-30 Aché Laboratórios Farmacêuticos S.A. compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas
CN115304652A (zh) * 2022-07-25 2022-11-08 福建华闽晟业生物科技有限公司 一种利用巨菌草制备野芝麻新甙的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703543A (en) * 1969-11-05 1972-11-21 American Home Prod Hydroxamic acids of alicyclic amino acids
IL57433A (en) * 1978-06-03 1982-08-31 Inst Rech Chim Biolog Pharmaceutical compositions containing cyclopentane derivatives
DE3030477C2 (de) * 1980-08-12 1986-10-16 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Iridoid-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung
JPH0366682A (ja) * 1989-08-04 1991-03-22 Tsumura & Co 新規イリドイド誘導体
AU651849B2 (en) * 1990-10-09 1994-08-04 Tsumura & Co. Iridoid derivatives and their use as medicines
DE19644422C2 (de) 1996-10-25 2000-06-15 Stefan Schulz Verwendung von Terpenen zur Behandlung von Autoimmunkrankheiten und bei Transplantat-Abstoßungsreaktionen
EP1145709A1 (de) * 2000-04-14 2001-10-17 Laboratoires Serobiologiques Verwendung von Naturstoffen zur Herstellung von kosmetischen Zubereitungen
DE60336549D1 (de) * 2002-05-10 2011-05-12 Council Scient Ind Res Hepatoprotektor aktivität von 2'-p-hydroxybenzoylmussaenosidsäure
EP1371372A1 (de) * 2002-06-08 2003-12-17 Cognis Iberia, S.L. Verwendung von Wirkstoffgemischen enthaltend Tocopherole und Extrakte des Harpagophytum procumbens zur Herstellung eines Medikamentes gegen rheumatische Arthritis
US7501222B2 (en) * 2005-06-24 2009-03-10 Dongjin Semichem Co., Ltd. Photoresist monomer polymer thereof and photoresist composition including the same
JP2008024670A (ja) * 2006-07-24 2008-02-07 Daiwa Kagaku Kogyo Kk 害虫駆除剤
US8552210B2 (en) * 2006-12-21 2013-10-08 E I Du Pont De Nemours And Company Hydrogenation of catmint oil
BRPI0700767B8 (pt) 2007-02-15 2021-05-25 Ache Laboratorios Farmaceuticos Sa composição farmacêutica, produto farmaceutico, processo para obtenção de compostos farmaceuticos e uso de tais compostos para o tratamento do vitiligo
KR101406933B1 (ko) * 2011-09-02 2014-06-12 동국대학교 산학협력단 라카아제를 이용한 새로운 효소형 시간-온도 이력지시계
CN103120699B (zh) * 2011-11-18 2017-04-19 天津市国际生物医药联合研究院 环烯醚萜类化合物在制备抗sars的药物中的应用
CN103690551A (zh) * 2013-07-18 2014-04-02 江苏大学 猪殃殃中环烯醚萜苷提取物及其提取方法和医药用途
DE102015102020A1 (de) * 2015-02-12 2016-08-18 Renate Wilmanowicz Immunologisch aktives Phyto-Gemisch und seine Anwendung bei der Prävention und in einem Verfahren zur Behandlung von Effloreszenzen
BR102017003318A2 (pt) 2017-02-17 2018-10-30 Aché Laboratórios Farmacêuticos S.A. compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas

Also Published As

Publication number Publication date
JP2023061959A (ja) 2023-05-02
CO2019008891A2 (es) 2020-01-17
CN110475768A (zh) 2019-11-19
IL268732B2 (en) 2024-12-01
SMT202200121T1 (it) 2022-07-21
PE20242300A1 (es) 2024-12-11
CL2019002309A1 (es) 2020-05-29
CY1125187T1 (el) 2023-06-09
BR112019017128A2 (pt) 2020-04-14
EP3583103A2 (en) 2019-12-25
IL268732B1 (en) 2024-08-01
AU2018221956A1 (en) 2019-08-29
AU2022201835A1 (en) 2022-04-07
US20200231561A1 (en) 2020-07-23
IL313974A (en) 2024-08-01
JP7349362B2 (ja) 2023-09-22
KR20250145126A (ko) 2025-10-13
BR102017003318A2 (pt) 2018-10-30
ES2909387T3 (es) 2022-05-06
RU2019129095A3 (es) 2021-10-27
JP7685540B2 (ja) 2025-05-29
RU2019129095A (ru) 2021-03-17
AU2018221956B2 (en) 2022-03-24
EP3583103B1 (en) 2022-01-12
EP4001270A1 (en) 2022-05-25
KR102882868B1 (ko) 2025-11-07
JP2020507607A (ja) 2020-03-12
RS63162B1 (sr) 2022-05-31
DK3583103T3 (da) 2022-03-14
SG11201907375VA (en) 2019-09-27
SA519402443B1 (ar) 2023-02-08
AU2022201835B2 (en) 2024-05-30
PL3583103T3 (pl) 2022-08-01
MX2022012282A (es) 2022-10-27
KR20190121790A (ko) 2019-10-28
WO2018148816A3 (en) 2018-10-18
PT3583103T (pt) 2022-03-25
NZ756074A (en) 2025-10-31
HRP20220377T1 (hr) 2022-07-08
IL268732A (en) 2019-10-31
WO2018148816A4 (en) 2019-01-03
CA3259255A1 (en) 2025-04-04
WO2018148816A2 (en) 2018-08-23
CA3052713A1 (en) 2018-08-23
US12698265B2 (en) 2026-08-04
MX2019009655A (es) 2020-07-24
ZA201906106B (en) 2020-08-26
PE20200449A1 (es) 2020-02-28
ZA202501840B (en) 2025-10-29
SI3583103T1 (sl) 2022-07-29
LT3583103T (lt) 2022-04-25
CN110475768B (zh) 2023-12-01

Similar Documents

Publication Publication Date Title
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2018001230A1 (es) Tratamiento de osteoartritis
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
MX387144B (es) Promotor novedoso y usos del mismo.
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
CO2017001884A2 (es) Polimorfos de selinexor
GT201700107A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
CL2020001290A1 (es) Método para el tratamiento de enfermedades gastrointestinales con tradipitant.
HUE060248T2 (hu) Eljárás növényi kivonatok elõállítására
MX382313B (es) Derivados del sobetiroma.
MX2019012428A (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
MY195000A (en) Method for the treatment of neurological disease
ZA202501840B (en) Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2017014830A (es) Metodo para tratar las enfermedades roya del cafe, mancha negra de los citricos, sarna de los citricos y sigatoka negra de la banana.
CO2020004984A2 (es) Proceso para preparar el benzotiofen-2-il boronato
MX2017003100A (es) Composiciones terapeuticas y nutricionales para trastornos gastrointestinales funcionales.
MX2016016118A (es) Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo.
MX2019006143A (es) Metodos de administracion de tratamiento antifibrotico.